Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three investor conferences in September:

Baird 2019 Global Healthcare ConferenceDate: Thursday, September 5Time: 7:55 a.m. ETLocation: New York, NY

Morgan Stanley 17th Annual Global Healthcare ConferenceDate: Tuesday, September 10Location: New York, NY

Ladenburg Thalmann 2019 Healthcare ConferenceDate: Tuesday, September 24Time: 3:30 p.m. ETLocation: New York, NY

Live audio webcasts of the Baird and Ladenburg Thalmann presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena PharmaceuticalsAllena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor ContactHannah DeresiewiczStern Investor Relations, Inc.212-362-1200[email protected]

Media ContactAdam Daley Berry & Company Public Relations 212-253-8881[email protected]

Source: Allena Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
• Cogent Communications Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cogent Communications Holdings, Inc.
• PROCEPT BioRobotics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT